By Laura B. Dunn, MD
Neuropsychiatric Update: Neuroimaging Schizophrenia
By Shawn J. Kile, MD
Genetics of Schizophrenia: Recent Advances
By Amy Eisener, BS, Michele T. Pato, MD, Helena Medeiros, MSW, Celia Carvalho, MS, and Carlos N. Pato, MD
Gender and Schizophrenia
By Carla M. Canuso, MD and Gahan Pandina, PhD
Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder
By Christoph U. Correll, Richard C. Josiassen, Grace S. Liang, Joshua Burke, Christopher F. O’Brien
Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder
By Richard C. Josiassen, John M. Kane, Grace S. Liang, Joshua Burke, Christopher F. O’Brien
Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder
By John M. Kane, Christoph U. Correll, Grace S. Liang, Joshua Burke, Christopher F. O’Brien
Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole Lauroxil
By Henry A. Nasrallah, Ralph Aquila, Arielle D. Stanford, Hasan H. Jamal, Peter J. Weiden, Robert Risinger
A Phase-1 Study Comparing Pharmacokinetic and Safety Profiles of Three Different Dose Intervals of Aripiprazole Lauroxil
By Robert Risinger, Marjie Hard, Peter J. Weiden
Asenapine in the Treatment of Negative Symptoms of Schizophrenia: Clinical Trial Design and Rationale
By Larry Alphs, MD, PhD, John Panagides, PhD, and Scott Lancaster, MS
Risperidone: Review of Its Therapeutic Utility in Depression
By Joyce E. Myers, MD, and Michael E. Thase, MD
Schizophrenia and Valproate
By Leslie Citrome, MD, MPH